Cempra Inc  

(Public, NASDAQ:CEMP)   Watch this stock  
Find more results for CEMP
+0.44 (4.77%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.13 - 9.88
52 week 5.97 - 15.39
Open 9.24
Vol / Avg. 337,387.00/252,268.00
Mkt cap 321.05M
P/E     -
Div/yield     -
EPS -1.49
Shares 33.20M
Beta     -
Inst. own 80%
May 20, 2014
Cempra Inc annual meeting of shareholders - 4:00PM EDT - Add to calendar
Apr 27, 2014
Q1 2014 Cempra Inc Earnings Release (Tentative) Add to calendar
Apr 9, 2014
Cempra Inc at Needham Life Sciences Conference
Mar 28, 2014
Cempra Inc at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference
Mar 12, 2014
Cempra Inc at Barclays Healthcare Conference
Mar 11, 2014
Cempra Inc at EBD BIO-Europe Spring
Mar 10, 2014
Cempra Inc at ROTH Conference
Mar 3, 2014
Cempra Inc at Cowen Health Care Conference
Feb 27, 2014
Q4 2013 Cempra Inc Earnings Conference Call
Feb 27, 2014
Q4 2013 Cempra Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -811.85% -576.41%
Operating margin -778.93% -549.35%
EBITD margin - -548.84%
Return on average assets -63.95% -53.06%
Return on average equity -86.52% -70.51%
Employees 38 -
CDP Score - -


CHAPEL HILL, NC 27517-8149
United States - Map
+1-919-3136601 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cempra, Inc., formerly Cempra Holdings, LLC, is a development-stage and clinical-stage pharmaceutical company focused on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic and acute staphylococcal infections. Its program CEM-101 is developing in both oral and intravenous (IV), formulations initially for the treatment of community-acquired bacterial pneumonia (CABP). Its second program is Taksta, which is developing in the United States as an oral treatment for bacterial infections caused by Staphylococcus aureus (S. Aureus), including methicillin-resistant S. aureus (MRSA). As of January 30, 2012, the Company completed a Phase II clinical trial in, which the oral formulation of CEM-101 demonstrated comparable efficacy to the levofloxacin. As of January 30, 2012, its second program Taksta has completed a Phase II clinical trial in patients.

Officers and directors

Garheng Kong M.D., Ph.D. Independent Chairman of the Board
Bio & Compensation  - Reuters
Prabhavathi B. Fernandes Ph.D. President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Mark M. Hahn Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
David S. Moore Executive Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Shane Barton Chief Accounting Officer, Controller
Bio & Compensation  - Reuters
Michael R. Dougherty Director
Age: 55
Bio & Compensation  - Reuters
David N. Gill Independent Director
Age: 56
Bio & Compensation  - Reuters
Dov A. Goldstein M.D. Independent Director
Age: 45
Bio & Compensation  - Reuters
John H. Johnson Independent Director
Bio & Compensation  - Reuters
Richard S. Kent M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters